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Abstract
Aims—To develop and evaluate the performance of a panel of isothermal real-time recombinase 
polymerase amplification (RPA) assays for detection of common bacterial urinary tract infection 
(UTI) pathogens.
Methods and Results—The panel included RPAs for Escherichia coli, Klebsiella pneumoniae, 
Proteus mirabilis, Pseudomonas aeruginosa, and Enterococcus faecalis. All five RPAs required 
reaction times of under 12 minutes to reach their lower limit of detection of 100 genomes per 
reaction or less, and did not cross-react with high concentrations of non-target bacterial genomic 
DNA. In a 50-sample retrospective clinical study, the five-RPA assay panel was found to have a 
specificity of 100% (95% CI, 78%-100%) and a sensitivity of 89% (95% CI, 75%-96%) for UTI 
detection.
Conclusions—The analytical and clinical validity of RPA for the rapid and sensitive detection 
of common UTI pathogens was established.
Significance and Impact—Rapid identification of the causative pathogens of urinary tract 
infections (UTIs) can be valuable in preventing serious complications by helping avoid the 
empirical treatment necessitated by traditional urine culture’s 48–72 hour turnaround time. The 
routine and widespread use of RPA to supplement or replace culture-based methods could 
profoundly impact UTI management and the emergence of multidrug-resistant pathogens.
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INTRODUCTION
Urinary tract infections (UTIs) annually affect 150 million people worldwide, and accounted 
for an estimated 10.5 million office visits and 2–3 million emergency department visits in 
the United States in 2007.(Stamm and Norrby, 2001, Schappert and Rechtsteiner, 2011, 
Niska et al., 2010) UTIs, which can be symptomatic or asymptomatic, are a notable cause of 
morbidity in infant or elderly males, and females of all ages.(Foxman, 2010) Sequelae range 
in severity from frequent recurrences to renal scarring and life-threatening sepsis.(Foxman, 
2002) For most UTIs, antibiotics are the most recommended and effective treatment option 
following diagnosis.(Foxman, 2010)
The diagnosis of UTIs is currently based on clinical symptoms, nonculture methods such as 
dipstick tests for nitrites or leukocyte esterase activity, and pathogen detection/identification 
by the gold standard urine culture method. Clinical symptoms overlap with other non-
infectious conditions and therefore have poor specificity, while dipstick tests, which don’t 
identify pathogens, are known to have poor positive predictive values despite being useful to 
rule out infections.(Devillé et al., 2004, Semeniuk and Church, 1999, Zaman et al., 1998) 
Urine cultures, while mostly accurate, can take up to 72 hours to provide a result. 
Consequently, initial UTI treatments are mostly empirical and broad-spectrum in nature with 
the goal of reducing the duration of patient discomfort. This widespread, injudicious use of 
antibiotics has accelerated the emergence of multidrug-resistant UTI pathogens.(Chen et al., 
2013) It is clear that methods for rapid UTI pathogen detection and identification at the 
point-of-care or in a clinical laboratory could help avoid imprecise treatments, and thereby 
have a positive impact on UTI management.
There is an increase interest in developing rapid UTI diagnostics to supplement or replace 
urine cultures. Various assays based on electrochemical biosensing, mass spectrometry, 
microcalorimetry, Raman spectroscopy, and real-time PCR have been recently reported.
(Liao et al., 2006, Burillo et al., 2014, Wang et al., 2013, Bonkat et al., 2012, Kloß et al., 
2013, Lehmann et al., 2011, Lehmann et al., 2010) Among these, real-time PCR and other 
nucleic acid amplification techniques (NAATs) are already well-established in clinical 
diagnostics, and have recently been developed into automated multiplex-capable platforms 
suitable for use in near-patient settings.(Tang et al., 1997, Raja et al., 2005, Poritz et al., 
2011) Isothermal NAATs, which offer performance comparable to PCR and a much faster 
time-to-result in many cases, are more amenable to low complexity, small-footprint devices 
due to the lack of thermal cycling requirements.(Niemz et al., 2011, Kim and Easley, 2011, 
Craw and Balachandran, 2012, Asiello and Baeumner, 2011, Gill and Ghaemi, 2008) Of the 
DNA-specific isothermal NAATs, RPA stands out by virtue of being the least complex to 
design and optimize, and the fastest-to-result.
RPA uses T4 phage recombinases UvsX and UvsY to facilitate the site-specific strand 
invasion of 30–35 nt primers into a DNA template, following which the strand-displacing 
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Sau polymerase (Staphylococcus aureus) mediates primer extension; the cyclic repetition of 
this process at a constant temperature of 37–42°C yields dsDNA amplicons exponentially as 
in PCR. In end-point RPA, agarose gel electrophoresis is used to visualize amplified DNA 
after 20–30 minutes. In real-time RPA, recombinases facilitate the hybridization of 46–52 nt 
long TwistAmp exo probes to either the positive or negative sense strand of the target 
amplicon. TwistAmp exo probes are oligonucleotides carrying a fluorophore and quencher 
separated by an abasic nucleotide analog (tetrahydrofuran, THF) located approximately 15 
nt upstream of the 3’ end. Following target hybridization, the double-strand-specific 
Escherichia coli exonuclease III recognizes and cleaves the THF site, releasing the quencher 
and resulting in the amplification-dependent development of fluorescence.(Piepenburg et al., 
2006)
In this paper, we describe the development of a panel of highly sensitive and specific exo 
probe-based real-time RPA assays for the detection of five bacterial pathogens that are 
among the most commonly implicated etiologic agents of UTIs. These pathogens – 
Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Pseudomonas aeruginosa, and 
Enterococcus spp. - were collectively detected in 84% and 85% of North American and 
European UTI samples respectively in the SENTRY Antimicrobial Surveillance Program;
(Fluit et al., 2000, Jones et al., 1999) they could be more or less frequent in specific patient 
populations. All five real-time RPA assays were able to detect 100 genomes per reaction or 
less, and showed no cross-reactivity with high concentrations of non-target genomic DNA. 
In a pilot retrospective study for clinical evaluation, the assay panel was found to have a 
specificity of 100% (95% CI, 78%-100%) and a sensitivity of 89% (95% CI, 75%-96%) for 
the detection of a UTI.
MATERIALS AND METHODS
Quantitative genomic DNA standards
For analytical sensitivity and specificity determination, standards were generated by 
isolation and purification of genomic DNA (gDNA) from bacterial colonies grown on 
culture plates. 5% sheep blood agar plates (Beckton, Dickinson and Company, NJ) were 
streaked with American Type Culture Collection (ATCC; Manassas, VA) strains of E. coli 
(ATCC 35218; 4.64 Mbp genome), P. aeruginosa (ATCC 27853; 6.3 Mbp genome), K. 
pneumoniae (ATCC 700603; 5.3 Mbp genome), E. faecalis (ATCC 29212; 3.3 Mbp 
genome), and P. mirabilis (ATCC 25933; 4.1 Mbp genome), and incubated overnight at 
37°C. An UltraClean® Microbial DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA) 
was used, following the manufacturer’s protocol, to isolate pure gDNA of each pathogen. 
The absorbances of extracted gDNA samples at 230 nm, 260 nm, and 280 nm (A230, A260 
and A280) were obtained using a Nanodrop 1000 instrument (NanoDrop Instruments, 
Wilmington, DE). Both A260/A280 and A260/A230 values were near or greater than 2.0 for 
all samples, indicating negligible contamination by proteins or organic solvents. The 
concentration, in genome copies/µL, of each reference strain’s pure gDNA stock was 
calculated using A260 values, the extinction coefficient of double stranded DNA (0.020 
µg−1.mL.cm−1), the average molar mass of double stranded DNA (650 Daltons/base pair), 
the genome size of each reference strain, and the Avogadro constant. Appropriate dilutions 
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of these stocks were made, using deionized water, and stored at −20°C as quantitative gDNA 
standards in 5 µL aliquots containing 107, 106, 105, 104, 103, 102 or 10 genomes each.
RPA primer and probe design
A combination of publicly-available bioinformatics tools, end-point RPA, confirmatory 
Sanger sequencing of amplicons, and real-time RPA was used for primer and TwistAmp exo 
probe design. Species-specific genes with sequence regions highly conserved between 
different strains were chosen for amplicon design. Publicly-available GenBank reference 
sequences of these genes (http://www.ncbi.nlm.nih.gov/genbank) were downloaded and 
aligned, if necessary, using SeaView software.(Gouy et al., 2010) The National Center for 
Biotechnology Information’s (NCBI) BLAST tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi, 
last accessed September 21, 2015) was used to verify that the downloaded reference 
sequences were homologous to all publicly-available sequences of the gene. The target 
genes’ most highly conserved regions were used for primer design, either manually or using 
NCBI’s primer-BLAST tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/, last accessed 
September 21, 2015), while exo probes were designed manually.(Ye et al., 2012) Secondary 
structure prediction and free energy calculations were performed using UNAfold software, 
which is freely available through the OligoAnalyzer tool (http://www.idtdna.com/analyzer/
Applications/OligoAnalyzer, last accessed September 21, 2015).(Markham and Zuker, 2008, 
Owczarzy et al., 2008)
RPA primers were designed to be between 30 and 35 nt long (for optimal recombinase 
activity), with GC content between 30 and 70% and either a G or a C at the 3’ end to provide 
a more stably clamped target for the polymerase. Sequence elements likely to contribute to 
hairpin-like secondary structures or primer-primer interactions were avoided. For each target 
gene, two or three sets of forward and reverse primers were designed to overlap a 150–250 
bp conserved region in a staggered manner. To lower the possibility of non-specifically 
amplifying human DNA or unrelated UTI pathogens, the sequence-specificity of all 
designed primers was evaluated by performing a BLAST search against publicly available 
nucleotide sequences of the following species: Homo sapiens, Escherichia coli, Proteus 
mirabilis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis, 
Enterococcus faecium, Citrobacter freundii, Enterobacter cloacae, Acinetobacter baumannii, 
Staphylococcus aureus, Providencia rettgeri, Providencia stuartii, Morganella morganii, and 
Streptococcus agalactiae. Primers that had less than 6 overall mismatches to a non-target 
sequences and/or less than 4 mismatches to a non-target sequence in the last 6 nucleotides at 
the 3’ end were rejected. Primers were purchased from Integrated DNA Technologies 
(Coralville, IA).
For verification of RPA product specificity, and to aid exo probe design, the outermost 
primers designed for each target gene were used in end-point RPA using purified gDNA as 
the template, followed by Sanger sequencing of the amplification product. End-point RPA 
was performed in a 50 µL volume using TwistAmp Basic kits (TwistDx, Cambridge, UK). 
Master mixes containing 480 nmol.l−1 RPA primers and TwistAmp rehydration buffer were 
prepared and distributed, in 42.5 µL volumes, into 0.2 mL reaction tubes containing dried 
enzyme pellets. The enzyme pellet in each tube was rapidly solubilized by pipetting the 
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master mix up and down upon addition. Subsequently, 5 µL of template was added to the 
tubes. 2.5 µL of magnesium acetate (bringing the concentration of Mg2+ to 14 mmol.l−1) 
was then pipetted into the tube lids, centrifuged into the tubes using a mini centrifuge, and 
immediately placed into a PCR thermal cycler (Bio-Rad Laboratories, Hercules, CA) 
programmed to operate at 42oC for 30 minutes. RPA products were purified using a PCR 
purification kit (Qiagen, Valencia, CA) and bi-directionally Sanger-sequenced (SeqWright, 
Houston, Texas). Sanger sequencing results were used to confirm amplicon size and 
homology to GenBank sequences at a single-nucleotide level. Using these sequences, 
TwistAmp exo probes (46–52 nt) were designed to be homologous to the positive- or 
negative-sense strands of the target regions flanked by the primers, and not to overlap with 
the primers themselves. All probes (synthesized by LGC Biosearch Technologies) contained 
a dT-FAM (thymine labeled with 6-carboxyfluorescein), and a dT-BHQ1 (thymine labeled 
with Black Hole Quencher®-1, which quenches FAM in close proximity) separated by a 
THF cleavable linker; they also contained a three carbon spacer at the 3’ end to block 
polymerase-mediated extension. OligoAnalyzer was used to analyze secondary structures 
and their free energies.
Real-time RPA experiments and data analysis
Real-time RPA reactions were performed in 50 µL volumes using TwistAmp exo kits 
(TwistDx, Cambridge, UK). Master mixes containing 420 nmol.l−1 RPA primers, 120 
nmol.l−1 RPA exo probes, and Twist Amp rehydration buffer were prepared and distributed, 
in 42.5 µL volumes, into reaction tubes supplied with dried enzyme pellets. 5 µL of template 
(quantitative gDNA standards or total DNA from clinical sample) was then added to the 
tubes. The 5 µL aliquot has been optimized for detecting between 102 to 106 CFU.ml−1 in 
urine. To start the reaction, 2.5 µL of magnesium acetate was added to each tube (to bring 
the total Mg2+ concentration to 14 mmol.l−1 ) by pipetting into tube lids and centrifuging 
immediately before placing the tubes in an Agilent MxPro 3005 real-time PCR machine 
(Agilent Technologies, Santa Clara, CA). The real-time PCR machine was programmed to 
run for 20 minutes at 42°C and collect fluorescence data at 10 s intervals.
Fluorescence data from real-time RPA assays using different exo probes was normalized 
(subtraction of baseline function from raw fluorescence) and thresholded individually, using 
MxPro software (Agilent Technologies, Santa Clara, CA). Baseline functions for each probe 
were calculated by fitting the raw fluorescence data obtained between 2 and 3 minutes from 
the beginning of the reaction to a line using a linear least mean squares algorithm. This 
baseline function was subtracted from the raw fluorescence (R) function to obtain baseline-
corrected fluorescence (dR). A 9-point moving average was applied to smooth the 
amplification curve that plotted baseline-corrected fluorescence (dR) against time. Threshold 
times (analogous to threshold cycles in real-time PCR) represented the times, from the 
beginning of reactions, at which the baseline-corrected fluorescence exceeded a threshold 
value located in the exponential growth regions of amplification curves. Threshold values of 
dR were empirically set to be between 25 and 100 standard deviations above background 
fluorescence for each exo probe, and used consistently thereafter.
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Determination of analytical sensitivity and specificity
The analytical sensitivities (limits of detection) of the panel of real-time RPA assays were 
estimated by performing real-time RPA on three to six replicates of different ten-fold serial 
dilutions of the quantitative gDNA standards, from 107 genome copies per reaction down to 
10 genome copies per reaction. The threshold time was plotted against genome copies 
detected, and a semi-log regression was calculated. For analytical specificity determination, 
each assay on the panel was performed in triplicate using 106 genome copies of non-target 
gDNA, from each other pathogen on the panel individually, as the template.
Clinical evaluation of RPA panel
The panel of the 5-RPA assays was clinically evaluated using 50 randomly selected clinical 
urine samples (from 50 unique patients) from among those collected by Medical Center 
Laboratories in Houston, Texas, between August 5 and August 18, 2014. These samples 
were collected from symptomatic and asymptomatic in- and outpatients in the Greater 
Houston area. The median age of the patients was 80.5 years (range 13–104 years); 70% of 
the patients were female. “Gold standard” comparison results were obtained by urine 
culture. Briefly, urine specimens were first inoculated on 5% sheep blood agar plates 
(Becton, Dickinson and Company, New Jersey) using an InfoLab 1 µL calibrated loop. 
Following aerobic incubation at 37°C for 12, 24 or 48 hours, a VITEK® 2 system 
(bioMérieux, Marcy l’Etoile, France) was used according to the manufacturer’s instructions 
to establish pathogen identity in what were considered “true positive” samples - culture-
positive plates with more than 10 colonies, indicating the presence of >104 CFU.mL−1 urine. 
If multiple pathogens were present, all pathogens were identified and reported.
Total DNA was extracted from clinical urine samples (within 12 hours of collection) using a 
simple, high-throughput method.(Lu et al., 2011) Briefly, 1 mL urine was pipetted into a 1.5 
ml microcentrifuge tube and centrifuged at 12,000 x g for 5 min. The supernatant was 
discarded and 100 µL lysis buffer (1% Tween-20, 1% NP-40, 0.03% SDS, 5% Chelex 100 
and 400 µg.mL−1 proteinase K) was added to the pellet and thoroughly mixed. The mixture 
was incubated at 56°C for 1 h, followed by 100°C for 10 min. The lysate was then 
centrifuged at 13,000 x g for 5 min, and 50 µL of the supernatant was aliquoted and stored at 
−20°C. The University of Houston’s Committee for the Protection of Human Subjects 
approved an application (No. 4228–14209) to exempt the RPA analysis of these samples 
from Institutional Review Board approval due to their de-identified nature. To test each 
clinical sample against the UTI RPA panel being evaluated, 5 µL of lysate supernatant was 
used as the template in five separate real-time RPA assays. Fluorescence data from the five 
tubes for each sample were normalized and thresholded as described above. A threshold 
time of less than 15 minutes in at least one reaction tube indicated a “positive” result, while 
no amplification above the threshold in all five tubes indicated a “negative” result. 
Sensitivity and specificity were calculated using the number of true positives (TP), false 
negatives (FN), false positives (FP), and false negatives (FN) as follows: Sensitivity = 
(TP)/(TP+FN); Specificity = (TN)/(TN+FP). Confidence intervals were calculated using the 
widely-used Wilson score method.(Wilson, 1927)
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RESULTS
RPA primer and probe design
The following species-specific target genes were used for amplicon design: chuA for E. coli, 
khe for K. pneumoniae, lasB for P. aeruginosa, ureR for P. mirabilis, and rpoA for 
Enterococcus spp.(Clermont et al., 2000, Braun et al., 2014, Shi et al., 2012, Zhang et al., 
2013, Naser et al., 2005) The most challenging primer and probe design was that for 
Enterococcus. Although twelve Enterococcus species have been identified as being 
pathogenic to humans, E. faecalis and E. faecium account for approximately 85–90% and 5–
10% of clinical enterococcal isolates, respectively.(Gin and Zhanel, 1996, Gold, 2001, 
Murray, 1990, Murray, 2000, Zhanel et al., 2003) Several candidate genes including atpD, 
phoE, ddl, rpoB, tuf, and rpoA were initially evaluated for RPA amplicon-appropriate 
conserved regions between E. faecalis and E. faecium (preliminary probe/primer design for 
Enterococcus spp not shown). rpoA was chosen because it had the least evenly spread 
mismatches between the enterococcal species; it also resulted in the most sequence-specific 
primers. For each pathogen on the panel, between six and nine primer pairs were screened 
for optimal performance using real-time RPA with quantitative gDNA standards as the 
template. Primer pairs that resulted in the shortest threshold times for the lowest 
concentration of gDNA were selected. Final amplicon lengths ranged from 161 to 211 bp, as 
shown in Table 1. Primer and probe sequences are indicated in Table 2.
RPA analytical sensitivity and specificity
Quantitative gDNA standards from reference strains were used to test the analytical 
sensitivities of all five real-time RPA assays. Three replicates were tested for gDNA 
concentrations ≥1000 genome copies per reaction, while six replicates were tested for 10 
and 100 genome copies per reaction. Threshold times were plotted against gDNA 
concentrations and fit to a semi-log regression line [Figure 1]. All replicates tested positive 
at gDNA concentrations ≥100 genome copies per reaction. Replicates for gDNA 
concentrations of 10 genomes copies per reaction for E. coli, E. faecalis, P. mirabilis, and P. 
aeruginosa were positive in 3/6, 5/6, 4/6, and 4/6 cases, respectively, putting the analytical 
sensitivity of those assays between 10 and 100 genome copies per reaction. All six replicates 
of the 10 genome copies per reaction sample were negative for the K. pneumoniae assay, 
putting its analytical sensitivity between 100 and 1000 genomes copies per reaction. Average 
threshold times for the lowest gDNA concentration detected by assays for E. coli, E. 
faecalis, P. mirabilis, P. aeruginosa, and K. pneumoniae were 9.5, 9.4, 8.6, 10.5, and 11.5 
minutes, respectively.
The analytical specificity of all RPAs was determined by cross-testing each primer/probe set 
against 106 genome copies per reaction of each panel UTI pathogen separately, i.e. E. coli 
(ATCC 35218), P. aeruginosa (ATCC 27853), K. pneumoniae (ATCC 700603), E. faecalis 
(ATCC 29212), and P. mirabilis (ATCC 25933). Only specific detection was observed; 
amplification curves for all non-specific reactions did not exceed threshold dR values during 
the 20 minute reaction time.
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Clinical evaluation of UTI RPA panel
In total, 50 urine samples were included in the study, with 36 true positives (72%) and 14 
true negatives (28%) as determined by urine culture for pathogen detection and VITEK 2 for 
pathogen identification. Of the 36 culture-positive plates analyzed by VITEK 2, 26 had 
monomicrobial growth, 9 had bimicrobial growth, and 1 had trimicrobial growth, with the 
identities of all pathogens reported. Total DNA was extracted from 1 mL of all 50 samples 
by the method described in the Materials and Methods section, following which 5 µL of 
extracted DNA from each sample (equivalent to 50 µL of urine) was used as the 
amplification template for RPA reactions targeting each of the five pathogens. 4/36 culture-
positive samples returned negative results from all five RPA reactions, and were considered 
false negatives. 1/4 false negatives was a M. morganii infection (not covered by the panel), 
while the others were samples containing E. coli, P. mirabilis, and K. pneumoniae. 32/36 
culture-positive samples returned at least one positive RPA reaction. 14/14 culture-negative 
samples returned negative results from all five RPA reactions. Based on these results, the 
overall clinical sensitivity and specificity for the detection of a UTI by the RPA panel can be 
estimated at 89% (95% CI, 75%-96%) and 100% (95% CI, 78%-100%), respectively [Table 
3].
Diagnostic accuracy analyses were also performed at a species specific level. Among the 
pathogens included in the RPA panel, Escherichia coli was the most commonly identified 
(n=14), followed by P. mirabilis (n=12), Enterococcus spp. and K. pneumoniae (n=5), and P. 
aeruginosa (n=2). Three pathogens not included in the RPA panel (M. morganii, S. aureus, 
and Group B Streptococcus) were identified by VITEK 2 in one monomicrobial sample and 
four polymicrobial samples. Table 4 shows the species-specific true- and false-positive and -
negative results, sensitivities, and specificities for each pathogen covered by the panel.
DISCUSSION
Culture-based detection and identification of UTI-causing pathogens is responsible for up to 
40% of the workload of clinical microbiology laboratories.(Wilson and Gaido, 2004) While 
it can be argued that cultures provide greater diagnostic reliability compared to dipstick 
methods, the 24- to 72-hour time span before the availability of culture results means they 
may have little impact on initial antibiotic therapy of 72 hour duration, which ends up being 
empirical and potentially inappropriate.(Burd and Kehl, 2011) Point-of-care testing panels 
for rapid identification of pathogens and/or antibiotic susceptibility – with assay targets 
determined by the setting (in-patient/out-patient), patient population (first-episode vs. 
recurrent infection, pediatric vs. adult, etc.), or severity (complicated vs. uncomplicated 
infection) – could therefore contribute significantly to lowering the clinical and economic 
burden of UTIs. In this study, we developed a panel of real-time recombinase polymerase 
amplification (RPA) assays for five of the most common bacterial UTI pathogens, and 
evaluated it in a small clinical study. We chose RPA over other isothermal NAATs such as 
loop-mediated isothermal amplification (LAMP) and helicase-dependent amplification 
(HDA) for the following reasons: faster enzyme kinetics for DNA amplification to a 
detectable level at low target concentrations – 10 minutes for RPA compared to 30–60 
minutes for LAMP and HDA;(Hill et al., 2008, Kim et al., 2011) easier oligonucleotide 
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design, with only three conserved regions required; easy availability of lyophilized reagents 
not requiring cold chain storage;(Crannell et al., 2014b) and ease of implementation in 
point-of-care-friendly devices and formats – examples include the ESEquant Tubescanner 
system, the lateral flow assay, and digital and centrifugal microfluidic platforms.(Euler et al., 
2012, Crannell et al., 2015a, Kalsi et al., 2015, Kim et al., 2014, Lutz et al., 2010) These 
advantages have made RPA a popular choice for infectious disease diagnostics, including 
assays for Klebsiella pneumoniae, Category A bioterrorism agents, Group B streptococci, 
Chlamydia trachomatis, HIV, and Cryptosporidium spp.(Valiadi et al., 2016, Euler et al., 
2013, Daher et al., 2014, Krolov et al., 2014, Crannell et al., 2014a, Rohrman and Richards-
Kortum, 2012) To the best of our knowledge, this is the first report on the development a 
panel of RPA assays specifically targeting UTI pathogens.
With regard to analytical sensitivity and specificity, the RPAs developed demonstrated limits 
of detection comparable to other RPAs for DNA amplification in the published literature 
(10–100 or 100–1000 molecules per reaction), and showed no cross-detection among the 
targets on the panel. The assays achieved their detection limits much faster than PCR or 
other isothermal NAATs, emphasizing the rapid reaction kinetics of the DNA polymerase 
and exonuclease enzymes used. The design of oligonucleotides for real-time RPA is as 
flexible as probe-based real-time PCR, with only three conserved regions required, as 
opposed to other isothermal NAATs like LAMP that require four to six primers. However, 
the long required length of the exo probe is a potential impediment to rapid design, 
especially for RPAs targeting multiple species with relatively low sequence homology. 
Longer oligonucleotides also make undesirable secondary structures with highly negative 
free energies much more likely, potentially affecting assay performance. The exo probe 
targeting K. pneumoniae, for example, was predicted to have a secondary structure (ΔG = 
−3.52 kcal mol−1) that creates a double-stranded neighborhood around the nucleotide to be 
replaced by exonuclease-cleavable THF [Figure 2]. This likely resulted in the assay for K. 
pneumoniae having a higher background fluorescence (data not shown) and worse analytical 
sensitivity compared to other assays on the panel.
In a retrospective clinical study using 50 urine samples of patients suspected of having UTIs, 
our panel of real-time RPA assays was determined to have a sensitivity and specificity of 
89% (95% CI, 75%-96%) and 100% (95% CI, 78%-100%), respectively, for UTI detection. 
A number of the urine-derived samples tested by the RPA panel could be expected to have 
had a high concentration of human DNA (due to pyuria) and DNA from non-pathogenic 
microbes (skin flora). High background DNA has been shown to lower RPA sensitivity, and 
might have been responsible for the false negative results among pathogens included on the 
panel.(Rohrman and Richards-Kortum, 2015) Another potential cause of the false negatives 
is the inhibitory effect of detergents on RPA enzymes, which can be overcome by adapting a 
different approach for sample preparation; for example, heating urine at 90°C for 5 minutes 
has been shown to be effective in releasing pathogen DNA.(Krolov et al., 2014)
It should be noted that we used a cut-off of ≥10,000 CFU.mL−1 of urine, as determined by 
colony counting on a culture plate, to designate a urine sample as being UTI-positive(Wilson 
and Gaido, 2004). Our current sample preparation method, in which total DNA from 50 µL 
of urine was used as the template for each RPA reaction, was optimized for this cut-off. 
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Lower and higher cut-offs in the range of 102 to 106 CFU.mL−1 are recommended for 
specific patient populations.(Stark and Maki, 1984, Coulthard et al., 2010, Hooton et al., 
2010) To avoid potential false positives and false negatives caused by testing samples 
outside the cut-off range sample preparation protocol would need to be modified to ensure 
greater enrichment (for cutoffs <104 CFU.mL−1) or dilution (for cut-offs >104 CFU.mL−1) 
of total urine-derived DNA per reaction. Semi-quantitative RPA, based on threshold time 
cut-off (analogous to semi-quantitative PCR), or fully quantitative RPA, based on internal 
positive controls, could be used to supplement alternate sample preparation methods.
(Hansen et al., 2013, Crannell et al., 2015b, Crannell et al., 2014c)
The accurate definition of an assay is imperative to ensure its clinical relevance. The panel 
of assays defined in this study covered a majority of the pathogens in the clinical samples 
tested; however, the samples included in the study were only representative of the 
predominantly geriatric patient population served by a single clinical microbiology 
laboratory in Houston. The etiology of UTIs can vary significantly by geography and patient 
age.(Kahlmeter, 2000, Langley et al., 2001) The healthcare setting from which the sample 
originates is also important – the higher propensity for complicated UTIs in in-patient 
settings like hospitals or assisted-living facilities such as nursing homes results in 
significantly different distributions of causative bacteria compared to ambulatory and out-
patient settings.(Flores-Mireles et al., 2015, Laupland et al., 2007, Wilson and Gaido, 2004) 
Our choice of pathogens might therefore not be optimal for other patient populations.
In summary, we have demonstrated the analytical and clinical validity of a panel of very 
rapid and highly sensitive real-time RPAs for the isothermal detection of common UTI 
pathogens. The ease of developing RPA assays, along with the plethora of formats available 
for easy implementation, make it an excellent tool to develop highly tailored panel of assays 
that targeti UTI pathogens and/or common antibiotic susceptibility genes. The routine and 
widespread use of RPA to supplement or replace culture-based methods could profoundly 
impact UTI management and the emergence of multidrug-resistant pathogens by obviating 
empirical broad-spectrum therapies.
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FIGURE 1. Analytical performance of real-time RPAs
(A) – (E): semi-log regression lines for detection of different dilutions of pathogens included 
on the UTI panel. Data points were derived from three replicates for 103 or more genome 
copies per reaction, and six replicates for 10 and 102 genome copies per reaction. (F) 
Representative amplification curves, averaged from three replicates, of different dilutions of 
E. faecalis gDNA.
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FIGURE 2. Most stable secondary structure of exo probe targeting K. pneumoniae
ΔG = −3.62 kcal mol−1; the transparent dotted circle (position 28) marks the nucleotide 
position replaced by THF and eventually cleaved by exonuclease III. RPA salt conditions 
− 14 mM Mg2+, 100 mM K+ – were used for secondary structure prediction.
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Table 1
Final RPA amplicon design
Pathogen Target
gene
Reference
sequence
Amplicon positions
in reference
sequence
Amplicon
length (bp)
E. coli chuA AF280396 1725–1936 212
K. pneumoniae khe AF293352 150–351 202
P. aeruginosa lasB JN118955 436–596 161
P. mirabilis ureR Z18752 1064–1258 195
E. faecalis rpoA NC_004668 211645–211841 197
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Table 2
RPA primers and probes.
Pathogen Sequence (5’-3’)
E. coli
F – ATATGGCGGTGAGTATTATCGTCAGGAACAACATC
R – GAGATGACCATTTGTCGGCATCAACATCTTTGTAG
P – AGCCCAAAACCGTACTCCTGAGTTTCGTTAG(FAM)H(BHQ)CCGGACGTAAGTTC
K. pneumoniae
F – TTATCCCGACAGCCCGGAGCGTTTTTCGATTGG
R – CAGCTTCCAGAGATAGCCGTTTATCCACACTTCCG
P – CACGCGGAGAGCGATGAGGAAGAGT(FAM)CH(BHQ)CTACGTGCTGGAGGGC
P. aeruginosa
F – GAGAATGACAAAGTGGAACTGGTGATCCGCCTG
R – GCCAGGCCTTCCCACTGATCGAGCACTTCGCCG
P – GAACAACATCGCCCAACTGGTCTACAACG(FAM)H(BHQ)CCTACCTGATTCCC
P. mirabilis
F – CAAAAACGCTCTATACTACACCATCAACATTAC
R – GTTTAAATGCGTCACAAAAATAAGCATTACTAC
P – GTCGCCATTTAAGTAAAGAGGGCGTTTCG(FAM)H(BHQ)TGCCAATTACTGTT
E. faecalis
F – GGACCCGCTACCGTGACTGCCGGCGATATTATCG
R – GAATCAACTGGAAGTACACCGATTGGCATATC
P – TCTGCTTGAACATAGCCACGACCAGGTTTCAC(FAM)H(BHQ)TAAGCGAGCATGGAA
F, forward primer; R, reverse primer; P – exo probe; (FAM), Fluorescein coupled to a thymine; H, terahydrofuran; (BHQ), Black Hole Quencher-1 
coupled to a thymine.
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Table 3
Detection of infection in 50 samples.
Microbiological culture (n = 50 samples)
Positive UTI Negative UTI Total
RPA panel (n = 50 samples)
Positive UTI 32 0 32
Negative UTI 4 14 18
Σ 36 14 50
Sensitivity (%) 89
Specificity (%) 100
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